SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential - 2FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 3The Best 10 Innovation Developments of the Year
- 4Philippines evacuates 3,000 villagers after volcano activity raises alert level
- 5Picking the Right Air Purifier for Your Home
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- EU delays signing of Mercosur free trade deal
- Four Dead in Last Month From Animal Attacks in Nepal
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
